ResearchMoz

United States Prosthetic Heart Valves Market Outlook to 2020

GlobalData
Published Date » 2014-05-09
No. Of Pages » 130
   
 "United States Prosthetic Heart Valves Market Outlook to 2020", provides key market data on the United States Prosthetic Heart Valves market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Mechanical Heart Valves, Tissue Heart Valves and Transcatheter Heart Valves. 
   
 The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Prosthetic Heart Valves market wherever available. 
   
 The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate...

Table of content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 What Is This Report About? 8
2.2 Prosthetic Heart Valves Market Segmentation 8
2.3 Definitions of Markets Covered in the Report 9

3 Prosthetic Heart Valves Market, United States 10
3.1 Prosthetic Heart Valves Market, United States, Revenue ($m), 2005-2012 10
3.2 Prosthetic Heart Valves Market, United States, Revenue ($m), 2012-2020 12
3.2.1 Mechanical Heart Valves Market, United States, Revenue ($m), by Segment, 2005-2012 14
3.2.2 Tissue Heart Valves Market, United States, Revenue ($m), by Segment, 2005-2012 16
3.2.3 Mechanical Heart Valves Market, United States, Revenue ($m), by Segment, 2012-2020 18
3.2.4 Tissue Heart Valves Market, United States, Revenue ($m), by Segment, 2012-2020 20
3.3 Prosthetic Heart Valves Market, United States, Volume (Units), 2005-2012 22
3.4 Prosthetic Heart Valves Market, United States, Volume (Units), 2012-2020 24
3.4.1 Mechanical Heart Valves Market, United States, Volume (Units), by Segment, 2005-2012 26
3.4.2 Tissue Heart Valves Market, United States, Volume (Units), by Segment, 2005-2012 28
3.4.3 Mechanical Heart Valves Market, United States, Volume (Units), by Segment, 2012-2020 30
3.4.4 Tissue Heart Valves Market, United States, Volume (Units), by Segment, 2012-2020 32
3.5 Prosthetic Heart Valves Market, United States, Average Price ($), 2005-2020 34
3.6 Prosthetic Heart Valves Market, United States, Distribution Share by Revenue ($m), 2011-2012 36
3.7 Prosthetic Heart Valves Market, United States, Company Share by Revenue ($m), 2011-2012 37

4 Overview of Key Companies in United States, Prosthetic Heart Valves Market 39
4.1 Edwards Lifesciences Corporation 39
4.1.1 Company Overview 39
4.2 Medtronic, Inc. 39
4.2.1 Company Overview 39
4.3 St. Jude Medical, Inc. 39
4.3.1 Company Overview 39
4.4 Sorin S.p.A. 40
4.4.1 Company Overview 40

5 Prosthetic Heart Valves Market Pipeline Products 41

6 Financial Deals Landscape 42
6.1 Debt Offerings 42
6.1.1 Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 42
6.1.2 Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 44
6.1.3 Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 46
6.1.4 Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 48
6.1.5 Edwards Lifesciences Completes Public Offering Of Notes Due 2018 For US$600 Million 50
6.1.6 St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 52
6.1.7 St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 54
6.1.8 Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 56
6.1.9 Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 58
6.1.10 Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 60
6.2 Partnerships 62
6.2.1 NeoChord Enters Into Licensing Agreement With Robarts Research Institute 62
6.3 Venture Financing 63
6.3.1 CorMatrix Cardiovascular Raises US$0.25 Million In Venture Financing 63
6.3.2 Cardiaq Valve Technologies Raises US$32.5 Million In Venture Financing 64

7 Recent Developments 65
7.1 Corporate Communications 65
7.1.1 Apr 08, 2014: CardiAQ Valve Technologies appoints Paul Cornelison as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs 65
7.1.2 Jan 28, 2014: St. Jude Medical Announces Organizational and Executive Leadership Changes 65
7.1.3 Jan 07, 2014: Simbionix Welcomes New Latin and Central American Sales Manager 66
7.1.4 Dec 05, 2013: Anxious Patient Group Calls on NICE to Approve Only Drug Treatment for Ultra-Rare Disease 66
7.1.5 Dec 05, 2013: Edwards Lifesciences Announces Appointment of CFO 68
7.1.6 Nov 04, 2013: Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 69
7.1.7 Aug 13, 2013: Covidien launches Barrx Channel RFA Endoscopic Catheter 69
7.1.8 Aug 02, 2013: China CDC Enters Into R&D Agreement With Aeras Global For TB Vaccine 70
7.1.9 Jul 22, 2013: St. Jude Medical Appoints Stefan Widensohler to Its Board of Directors 71
7.1.10 Jul 03, 2013: Novartis Files Patent Infringement Lawsuit Against Intas Pharma Over Generic Myfortic 71
7.1.11 May 14, 2013: Edwards Lifesciences CFO Thomas M Abate To Retire 72
7.1.12 May 08, 2013: Cardio3 BioSciences Raises US$9 Million In Series D Financing 72
7.2 Financial Announcements 74
7.2.1 Apr 24, 2014: Edwards Lifesciences Reports Strong First Quarter Results 74
7.2.2 Apr 16, 2014: St. Jude Medical Reports First Quarter 2014 Results 75
7.2.3 Feb 18, 2014: Medtronic Reports Third Quarter Earnings 77
7.2.4 Feb 03, 2014: Edwards Lifesciences Reports Strong Fourth Quarter Results 79
7.2.5 Jan 22, 2014: St. Jude Medical Reports Fourth Quarter and Full-Year 2013 Results 81
7.2.6 Dec 09, 2013: St. Jude Medical Announces Fourth Quarter Dividend 83
7.2.7 Nov 26, 2013: FDA approves Varithena (polidocanol injectable foam) for the treatment of patients with varicose veins 83
7.2.8 Nov 19, 2013: Medtronic Reports Second Quarter Earnings 84
7.2.9 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 86
7.2.10 Oct 28, 2013: Edwards Lifesciences Reports Solid Third Quarter Results 86
7.2.11 Oct 16, 2013: St. Jude Medical Reports Third Quarter 2013 Results 88
7.2.12 Oct 02, 2013: St. Jude Medical Announces Third Quarter 2013 Earnings Conference Call 90
7.2.13 Aug 20, 2013: Medtronic Reports First Quarter Earnings 90
7.2.14 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 92
7.2.15 Jul 30, 2013: Teleflex subsidiary receives 510(k) clearance for balloon dilatation catheters 92
7.2.16 Jul 30, 2013: St. Jude Medical Announces Third Quarter Dividend 93
7.2.17 Jul 25, 2013: Edwards Lifesciences Reports Solid Second Quarter Results 94
7.2.18 Jul 17, 2013: St. Jude Medical Reports Second Quarter 2013 Results 95
7.2.19 Jul 11, 2013: Edwards Lifesciences to Host Earnings Conference Call on July 25, 2013 97
7.2.20 Jul 02, 2013: St. Jude Medical Announces Second Quarter 2013 Earnings Conference Call 97
7.2.21 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 97
7.2.22 May 10, 2013: New Excimer Laser from ZEISS for Refractive Surgery Reduces Treatment Time to the Benefit Both Doctor and Patient 99
7.3 Government and Public Interest 101
7.3.1 Mar 11, 2014: Simbionix Provides Comprehensive Virtual Reality Training for the Fast Arthroscopy Curriculum 101
7.3.2 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference 101
7.3.3 Dec 18, 2013: St. Jude Medical to Present at the 32nd Annual J.P. Morgan Healthcare Conference 101
7.3.4 Dec 10, 2013: Collaboration Between Simbionix And 1st MSMU To Integrate A Russian Developed Assessment System To Enhance Laparoscopic Training 102
7.3.5 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference 102
7.3.6 Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 102
7.3.7 Nov 21, 2013: St. Jude Medical to Present at the Piper Jaffray 25th Annual Healthcare Conference 103
7.3.8 Nov 06, 2013: St. Jude Medical to Present at the 2013 Credit Suisse Healthcare Conference 103
7.3.9 Nov 01, 2013: St. Jude Medical to Present at the 2013 Credit Suisse Healthcare Conference 103
7.3.10 Oct 28, 2013: Edwards Lifesciences to Webcast Analyst Meeting at TCT 25 103
7.3.11 Oct 14, 2013: Edwards Lifesciences to Host Earnings Conference Call on October 28, 2013 103
7.3.12 Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference 103
7.3.13 Sep 04, 2013: St. Jude Medical to Present at the Stifel Healthcare Conference 103
7.3.14 Sep 03, 2013: St. Jude Medical to Present at the Morgan Stanley Global Healthcare Conference 104
7.3.15 Aug 12, 2013: Edwards Lifesciences to Present at the Canaccord Genuity Growth Conference 104
7.4 Legal And Regulatory 104
7.4.1 Apr 11, 2014: Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve 104
7.4.2 Mar 12, 2014: Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test 104
7.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures 105
7.4.4 Nov 14, 2013: Edwards Comments on German Appellate Court Ruling 105
7.4.5 Nov 07, 2013: Law Office of Brodsky & Smith Announces Investigation of Edwards Lifescience 106
7.4.6 Oct 19, 2013: Medtronic Statement on Medical Device Security 106
7.4.7 Oct 18, 2013: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Edwards Lifesciences Corporation 107
7.4.8 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records 107
7.4.9 Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. 107
7.5 Other Significant Developments 108
7.5.1 Feb 24, 2014: St. Jude Medical Announces Increase in Quarterly Dividend 108
7.5.2 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 108
7.5.3 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai 108
7.5.4 Dec 09, 2013: Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference 109
7.5.5 Dec 06, 2013: The Edwards Lifesciences Fund to Grant ~$5.6 Million to 450+ Non-Profit Organizations in 2013 111
7.5.6 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles 111
7.5.7 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 113
7.6 Product News 113
7.6.1 Mar 31, 2014: Study of transcatheter pulmonary valve shows strong results, reports U-M pediatric interventional cardiologist 113
7.6.2 Dec 27, 2013: Mymetics Enters Into Licensing Agreement With RSV For Respiratory Syncytial Virus Vaccine 114
7.6.3 Nov 18, 2013: Simbionix New ANGIO Mentor Suite Promotes Endovascular Team Training in a True-to-Life Clinical Environment 116
7.6.4 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 117
7.6.5 Nov 14, 2013: Endovascular Aneurysm Training Module Now Supports Vascutek's Anaconda Devices 117
7.7 Strategy And Business Planning 118
7.7.1 Nov 13, 2013: Edwards Lifesciences Expands Singapore Manufacturing Facility 118
7.7.2 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland 119
7.7.3 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 120
7.7.4 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation 121

8 Appendix 122
8.1 Research Methodology 123
8.1.1 Coverage 123
8.1.2 Secondary Research 123
8.1.3 Primary Research 124
8.1.4 Market Modeling and Forecasting 125
8.1.5 Company Share Analysis 128
8.1.6 Distribution Share Analysis 129
8.2 Expert Panel 130
8.3 GlobalData Consulting 130
8.4 Contact Us 130
8.5 Disclaimer 130

List of Tables


Table 1: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 11
Table 2: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 13
Table 3: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 15
Table 4: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 17
Table 5: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 19
Table 6: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 21
Table 7: Prosthetic Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 23
Table 8: Prosthetic Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 25
Table 9: Mechanical Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 27
Table 10: Tissue Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 29
Table 11: Mechanical Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 31
Table 12: Tissue Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 33
Table 13: Prosthetic Heart Valves Market, United States, Average Price ($), Historic, 2005-2012 34
Table 14: Prosthetic Heart Valves Market, United States, Average Price ($), Forecast, 2012-2020 35
Table 15: Prosthetic Heart Valves Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012 36
Table 16: Prosthetic Heart Valves Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012 38
Table 17: Prosthetic Heart Valves Market Pipeline Products 41
Table 18: Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 42
Table 19: Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 44
Table 20: Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 46
Table 21: Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 48
Table 22: Edwards Lifesciences Completes Public Offering Of Notes Due 2018 For US$600 Million 50
Table 23: St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 52
Table 24: St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 54
Table 25: Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 56
Table 26: Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 58
Table 27: Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 60
Table 28: NeoChord Enters Into Licensing Agreement With Robarts Research Institute 62
Table 29: CorMatrix Cardiovascular Raises US$0.25 Million In Venture Financing 63
Table 30: Cardiaq Valve Technologies Raises US$32.5 Million In Venture Financing 64
Table 31: Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country 125

List of Figures


Figure 1: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 10
Figure 2: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 12
Figure 3: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 14
Figure 4: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 16
Figure 5: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 18
Figure 6: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 20
Figure 7: Prosthetic Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 22
Figure 8: Prosthetic Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 24
Figure 9: Mechanical Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 26
Figure 10: Tissue Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 28
Figure 11: Mechanical Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 30
Figure 12: Tissue Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 32
Figure 13: Prosthetic Heart Valves Market, United States, Company Share (%), 2012 37
Figure 14: GlobalData Epidemiology-Based Forecasting Model 127
Figure 15: GlobalData Capital Equipment-Based Forecasting Model 128
Figure 16: Primary Interviews by Participant Type (%) 129

Upcoming Reports:

Greece: carbon dioxide market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the carbon dioxide market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the carbon dioxide market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of...
Zinc Citrate Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
By - Transparency Market Research
Zinc citrate is a stable, odorless, light colored crystalline powder with low solubility. Zinc citrate is primarily used as a source of zinc for various medical and dental applications. Zinc citrate is produced by neutralization reaction of citric acid with pure zinc followed by precipitation and dehydration. Citric acid is a colorless crystalline compound extracted from various bio sources including limes, lemons, etc. Zinc citrate is produced as dehydrate or trihydrate as per the end user application. Zinc is among the most essential mineral required for proper...
Pancreatic Cancer Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018
By - Transparency Market Research
The global pancreatic cancer drug market is projected to reach USD 1.2 billion by 2015. Among all the regions, the United States has recorded the maximum number of pancreatic cancer cases, which are about 30,000 patients each year. The survival rate is less than 5 years which acts as a major hurdle for the growth of this market. The aggressive nature of pancreatic cancer and inadequate responses to the treatment acts as major obstacles in the treatment of such diseases. Moreover, pancreatic cancer is diagnosed when it is in its advanced stage, leading to increase in...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Hitachi Readies New Suite of Driving Systems
Oct 16, 2014  
Japan’s Hitachi Automotive Systems is all set to unveil a line of innovative autonomous driving technologies as the trend of high-tech and automotive electronics takes the industry by storm. The suite of technologies were unveiled in northern Japan last week and included features such as no-hands self-parking, vehicle stability control in electric automobiles, precrash braking, and...
Canadas Agreement on Waste-Water Treatment Boosts Indias PM Pet Clean Ganga Project
Oct 16, 2014  
In 2008, Canada and India adopted a bilateral science and technology collaboration agreement for Scientific and Technological Cooperation.  The pet Clean Ganga project led by the Indian Prime Minister Narendra Modi has received a confident boost with an agreement earlier on Wednesday. The agreement is all about cleaning up the most heavily used river in the world between Canada...
China Sends Experimental Ebola Drugs to Aid Workers, to Increase Supply if Found Effective
Oct 16, 2014  
An experimental Ebola drug has been sent to Africa for use by Chinese aid worker by a Chinese drug manufacturer. The company is plans to undertake clinical trials of the drug to combat the deadly Ebola outbreak in West Africa that has claimed more than 4000 lives so far. Several thousand doses of the drug JK-05, manufactured by Sihuan Pharmaceutical Holdings Group Ltd, have been...
Broccoli Based Chemical Gives Hope For Treating Autism
Oct 15, 2014  
According to the inferences derived from a small scale clinical trial, the chemical that is extracted from the sprouts of broccoli possess certain anti-cancerous properties. Moreover, this chemical may be able to even treat behavioral symptoms in those suffering from autism spectrum disorders. This research study was carried out by the scientists of Johns Hopkins University School of Medicine...
Toyota China to Recall Crown Sedans Due to Leaking Brake Fluid Issue
Oct 15, 2014  
Joining the global wave of automobile recalls, Toyota has announced its decision to recall 93,700 cars from the Chinese market to fix an issue regarding leaking brake fluid, Chinese quality watchdog has informed.  Tianjin FAW Toyota Motor Co, the Chinese subsidiary of Toyota Motor Corp., will recall the Crown model sedans manufactured by it between 1st December 2009 and 14th June 2012....